Ligand Pharmaceuticals (LGND) Total Current Liabilities (2010 - 2026)

Ligand Pharmaceuticals has disclosed Total Current Liabilities across 17 years of filings, most recently posting $40.7 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $40.7 million, down 30.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $40.7 million (down 30.7% YoY), and the FY2025 annual result was $37.4 million, up 0.9% from the prior year.
• Total Current Liabilities came in at $40.7 million for Q1 2026 at Ligand Pharmaceuticals, up from $37.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $167.9 million in Q2 2022 to a low of $15.7 million in Q3 2023.
• The 5-year median for Total Current Liabilities is $37.4 million (2025), against an average of $55.0 million.
• Across the five-year window, Total Current Liabilities soared 272.6% in 2022 and sank 88.37% in 2023, its largest moves.
• Ligand Pharmaceuticals' Total Current Liabilities stood at $98.8 million in 2022, then slumped by 83.02% to $16.8 million in 2023, then soared by 121.14% to $37.1 million in 2024, then grew by 0.9% to $37.4 million in 2025, then rose by 8.6% to $40.7 million in 2026.
• The last three Total Current Liabilities figures came in at $40.7 million (Q1 2026), $37.4 million (Q4 2025), and $30.5 million (Q3 2025), per Business Quant data.